XPO1 Inhibition Suppresses the Growth of Pancreatic Neuroendocrine Tumors

Md. Hafiz Uddin1, Sahar Bannoura3, Amro Aboukameel2, Mohammed Najeeb Al-Hallak1, Yosef Landesman2, Ramzi M. Mohammad1, Philip A. Philip1, Bassel El-Rayess3, Asfar S. Azmi1,2

1Department of Oncology, Wayne State University School of Medicine, Detroit MI 48201 USA; 2Karyopharm Therapeutics Inc., Newton, MA 02459, USA; 3Emory Winship Cancer Institute, Atlanta, Georgia.

Abstract
Pancreatic neuroendocrine tumors (PNETs) are rare islet cell tumors. Although slow growing in early stages, the overall survival rates of metastatic PNETs are dismal, low at 25%. The main treatment option includes surgery followed by chemotherapy or targeted therapy. Unfortunately, advanced PNETs show minimal response to FDA approved therapies suggesting the urgent need for identification of novel and effective treatments. In the present study, we have tested 1st and 2nd generation XPO1 inhibitors also as selective inhibitor of nuclear export (SINE) on BON1 and QGP1 PNET tumor cells. The IC50 for SINE compounds namely KPT-185, KPT-330 (selinexor/XPOVIO), KPT-8602 (eltanexor) were 26 nM, 283 nM, 1027 nM respectively for BON1 cells. Similar trends in the IC50 were observed in QGP1 cells. Both the 1st and 2nd generation SINE, KPT-330 and KPT-8602 reduced the number and area of the colonies significantly. SINE compounds were able to induce apoptosis at pharmacologically relevant concentrations. Western blot analysis also revealed significant induction of PARP cleavage by SINE. The NET marker Chromogranin A was found to be reduced in the SINE treated cells in IF assay. XPO1 inhibitors also suppress pmTOR and pPTSS6K by mTORC2 pathway molecule BICTOR in QGP1 cells. Taken together, this is the first study to reveal the therapeutic potential of novel XPO1 targeted agents for the treatment of PNETs. The in vivo evaluation of SINE compounds in xenograft models are underway.

Materials and Methods
- Growth inhibition was determined by MTT assay. Dose response non-linear curves were generated and IC50 were calculated using GraphPad Prism software.
- Colony forming ability was determined by clonogenic assay. No of colonies and area of the colonies were determined by NIH imageJ software.
- Apoptotic cell death was determined by flow cytometric analysis using annexin V and propidium iodide.
- Western blotting analysis was performed to detect protein levels.
- Expression of PNET marker Chromogranin A was determined using immunofluorescence (IF) technique.

Results

Figure 1. Schematic diagrams. A. Diagram of nuclear pore complex (NPC). B. Electron micrograph of NPC. C. Mechanism of nuclear export: 1) Exportin-1 (CRM1/XPO1) hydrophobic groove binds to the leucine rich nuclear export signal (NES) domain of the cargo proteins. RanGTP and protein cargos bind to exportin-1 forming stable ternary and activate it by 3D conformational change. 2) Activated complex binds to NPC, a large supramolecular complex composed of more than 30 different proteins, the nucleoporins. 3) XPO1-complex passes through NPC and enters cytoplasm. 4) In the cytoplasm, the ternary exportin-1–cargo-RanGTP complexes are dissociated. Excessive nuclear export by XPO1 causes mislocalization dependent inactivation of tumor suppressors. Selective inhibitor of nuclear export (SINE) compounds (KPT-8602) bind to XPO1 and block nuclear export function. D. Structure of next generation SINE compound KPT-8602 (eltanexor).

Figure 2. Selective inhibitor of nuclear export (SINE) compounds (KPT-185, KPT-330 and KPT-8602) induced growth inhibition in pancreatic neuroendocrine tumors (PNET) cells. Leptomycin B (LMB) is the irreversible inhibitor of XPO1 and was used as a positive control. A. BON1 cells. B. QGP1 cells. Cells were treated with varying doses of drugs for 72 hours. MTT assay was performed to determine the growth inhibition.

Figure 3. Colony formation ability in BON1 and QGP1 cells under KPT-330 and KPT-8602 treatment. A.D: Representative colonies. B.E: Bar diagram showing the number of colonies with indicated doses of drugs. C-F: Bar diagram showing the average area of the colonies with indicated doses of drugs.

Figure 4. Apoptotic cell deaths in PNET cells under KPT-330 and KPT-8602 treatment. A. Bar diagram showing the apoptotic cell deaths in BON1 cells. B. Representative FACS images. C. Western blot analysis of PARP cleavage in BON1 and QGP1 cells. Cells were treated with KPT-330 and KPT-8602 with a concentration of 280 nM and 1000 nM respectively for 72 hours.

Figure 5. Western blot analysis of mTOR pathway associated proteins in BON1 and QGP1 cells treated with KPT-330 and KPT-8602. Cells were treated with KPT-330 and KPT-8602 with a concentration of 280 nM and 1000 nM respectively for 72 hours. Cell lysis was done in RIPA buffer with inhibitors.

Figure 6. Immunofluorescence (IF) detection of Chromogranin A in QGP1 cells treated with KPT-330 and KPT-8602. Cells were grown in poly-L-lysine coated chamber slide, treated with indicated concentration of SINE compounds for 24h. Fixation was done in 4% paraformaldehyde and stained with 1:100 dilution of Chromogranin A (green) antibody. Nucleus was stained with DAPI (blue).

Conclusion
The current study is the first approach to target pancreatic neuroendocrine tumors (PNETs) using nuclear export inhibitors also known as selective inhibitor of nuclear export (SINE). Both the 1st and 2nd generation XPO1 inhibitors namely KPT-330 (selinexor/XPOVIO), KPT-8602 (eltanexor) were able to suppress the growth and induction of apoptosis in BON1 and QGP1 PNET tumor cells. These in vitro findings warrant further pre-clinical and clinical investigations to determine the effectiveness of SINE compounds in PNETs.

References

Acknowledgement
Work in the lab of Asfar S. Azmi is supported by R01CA24066701, NIMH R35 MH110738, Partners Funds and SRY Foundation Inc.